Parke-Davis and Company Pharmaceutical Company
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
gptkb:Warner-Lambert |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:defunct |
2000
|
| gptkbp:foundedIn |
1866
|
| gptkbp:founder |
gptkb:George_S._Davis
gptkb:Hervey_Parke |
| gptkbp:headquartersLocation |
gptkb:Detroit,_Michigan,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Parke-Davis and Company Pharmaceutical Company
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:notableContributor |
Development of the first systematic clinical trials
Standardization of pharmaceuticals Introduction of the first mass-produced epinephrine |
| gptkbp:notableEmployee |
Davis, George S.
Parke, Hervey C. |
| gptkbp:notableProduct |
gptkb:Chlorpromazine
gptkb:Benadryl gptkb:Lyrica gptkb:Dilantin Adrenalin |
| gptkbp:parentCompany |
gptkb:Pfizer
|
| gptkbp:bfsParent |
gptkb:Parke-Davis_Research_Laboratory
|
| gptkbp:bfsLayer |
8
|